Aerovate Therapeutics Inc
NASDAQ:JBIO

Watchlist Manager
Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc
NASDAQ:JBIO
Watchlist
Price: 9.89 USD 5.1% Market Closed
Market Cap: 9.1m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
N/A
Revenue
Forecast
N/A
Operating Income
Forecast
+34%
Net Income
Forecast
+33%

Wall Street
Price Targets

JBIO Price Targets Summary
Aerovate Therapeutics Inc

Wall Street analysts forecast JBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for JBIO is 18.36 USD with a low forecast of 17.17 USD and a high forecast of 19.95 USD.

JBIO Lowest Forecast
Wall Street Target
17.17 USD
74% Upside
JBIO Average Forecast
Wall Street Target
18.36 USD
86% Upside
JBIO Highest Forecast
Wall Street Target
19.95 USD
102% Upside
Lowest
Price Target
17.17 USD
74% Upside
Average
Price Target
18.36 USD
86% Upside
Highest
Price Target
19.95 USD
102% Upside
Aerovate Therapeutics Inc Competitors:
Price Targets
688366
Shanghai Haohai Biological Technology Co Ltd
47% Upside
B
BCAX
Bicara Therapeutics Inc
257% Upside
300841
Chengdu Kanghua Biological Products Co Ltd
29% Upside
ARGX
argenx SE
46% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
47% Upside
B
BCAX
Bicara Therapeutics Inc
257% Upside
300841
Chengdu Kanghua Biological Products Co Ltd
29% Upside
ARGX
argenx SE
46% Upside
RYTM
Rhythm Pharmaceuticals Inc
37% Upside
603087
Gan & Lee Pharmaceuticals
16% Upside
REGN
Regeneron Pharmaceuticals Inc
47% Upside
ORKA
Oruka Therapeutics Inc
250% Upside

Revenue
Forecast

Revenue Estimate
Aerovate Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Aerovate Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Aerovate Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-13%
Average Miss
What are analyst estimates?

See Also

Summary
JBIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
JBIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
JBIO stock valuation using valuation multiples.
Wall Street Estimates
JBIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
JBIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is JBIO's stock price target?
Price Target
18.36 USD

According to Wall Street analysts, the average 1-year price target for JBIO is 18.36 USD with a low forecast of 17.17 USD and a high forecast of 19.95 USD.

Back to Top
ALPHA SPREAD
Follow us
Join more than 263,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.